Infantile haemangioma
Summary With a prevalence of 4·5%, infantile haemangiomas are the most common benign tumours of infancy, arising in the first few weeks of life and exhibiting a characteristic sequence of growth and spontaneous involution. Most infantile haemangiomas do not require therapy. However, to identify at-r...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2017-07, Vol.390 (10089), p.85-94 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 94 |
|---|---|
| container_issue | 10089 |
| container_start_page | 85 |
| container_title | The Lancet (British edition) |
| container_volume | 390 |
| creator | Léauté-Labrèze, Christine, Dr Harper, John I, Prof Hoeger, Peter H, Prof |
| description | Summary With a prevalence of 4·5%, infantile haemangiomas are the most common benign tumours of infancy, arising in the first few weeks of life and exhibiting a characteristic sequence of growth and spontaneous involution. Most infantile haemangiomas do not require therapy. However, to identify at-risk haemangiomas, close follow-up is crucial in the first weeks of life; 80% of all haemangiomas reach their final size by 3 months of age. The main indications for treatment are life-threatening infantile haemangioma (causing heart failure or respiratory distress), tumours posing functional risks (eg, visual obstruction, amblyopia, or feeding difficulties), ulceration, and severe anatomic distortion, especially on the face. Oral propranolol is now the first-line treatment, which should be administered as early as possible to avoid potential complications. Haemangioma shrinkage is rapidly observed with oral propranolol, but a minimum of 6 months of therapy is recommended. |
| doi_str_mv | 10.1016/S0140-6736(16)00645-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1861511021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673616006450</els_id><sourcerecordid>1914872595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-de09b9cbae30588e47331ebc8c35a1cb241d1aaa7cc536fd201f69448dda324b3</originalsourceid><addsrcrecordid>eNqFkEtLAzEQgIMotlaPHhXBSz2szmweu3tRpPgoFDyo4C1ks7Oauo-6aYX-e7cPK_TiKQS--ZL5GDtBuERAdfUMKCBQEVd9VBcASsgAdlgXRSQCKaK3XdbdIB124P0YAIQCuc86YQxxIiLssuNhlZtq6go6-zBUmurd1aU5ZHu5KTwdrc8ee72_exk8BqOnh-HgdhRYIeJpkBEkaWJTQxxkHJOIOEdKbWy5NGjTUGCGxpjIWslVnoWAuUra0SwzPBQp77H-yjtp6q8Z-akunbdUFKaieuY1xgolIoTYoudb6LieNVX7O40JijgKZSJbSq4o29TeN5TrSeNK08w1gl5008tuehFFt7dlNw3t3OnaPktLyjZTv6Fa4GYFUJvj21GjvXVUWcpcQ3aqs9r9-8T1lsEWrnLWFJ80J_-3jfahhpVk4UC1NAD_AfTnjs4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1914872595</pqid></control><display><type>article</type><title>Infantile haemangioma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Léauté-Labrèze, Christine, Dr ; Harper, John I, Prof ; Hoeger, Peter H, Prof</creator><creatorcontrib>Léauté-Labrèze, Christine, Dr ; Harper, John I, Prof ; Hoeger, Peter H, Prof</creatorcontrib><description>Summary With a prevalence of 4·5%, infantile haemangiomas are the most common benign tumours of infancy, arising in the first few weeks of life and exhibiting a characteristic sequence of growth and spontaneous involution. Most infantile haemangiomas do not require therapy. However, to identify at-risk haemangiomas, close follow-up is crucial in the first weeks of life; 80% of all haemangiomas reach their final size by 3 months of age. The main indications for treatment are life-threatening infantile haemangioma (causing heart failure or respiratory distress), tumours posing functional risks (eg, visual obstruction, amblyopia, or feeding difficulties), ulceration, and severe anatomic distortion, especially on the face. Oral propranolol is now the first-line treatment, which should be administered as early as possible to avoid potential complications. Haemangioma shrinkage is rapidly observed with oral propranolol, but a minimum of 6 months of therapy is recommended.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(16)00645-0</identifier><identifier>PMID: 28089471</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Age ; Atrophy ; Babies ; Benign ; Distortion ; Feeding ; Heart diseases ; Heart Failure - etiology ; Hemangioma ; Hemangioma - drug therapy ; Hemangioma - epidemiology ; Humans ; Infant ; Internal Medicine ; Pathogenesis ; Propranolol ; Propranolol - therapeutic use ; Respiratory Distress Syndrome, Newborn - etiology ; Shrinkage ; Skin Ulcer - etiology ; Therapy ; Tumors ; Visual perception</subject><ispartof>The Lancet (British edition), 2017-07, Vol.390 (10089), p.85-94</ispartof><rights>Elsevier Ltd</rights><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jul 1, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-de09b9cbae30588e47331ebc8c35a1cb241d1aaa7cc536fd201f69448dda324b3</citedby><cites>FETCH-LOGICAL-c448t-de09b9cbae30588e47331ebc8c35a1cb241d1aaa7cc536fd201f69448dda324b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673616006450$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28089471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Léauté-Labrèze, Christine, Dr</creatorcontrib><creatorcontrib>Harper, John I, Prof</creatorcontrib><creatorcontrib>Hoeger, Peter H, Prof</creatorcontrib><title>Infantile haemangioma</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Summary With a prevalence of 4·5%, infantile haemangiomas are the most common benign tumours of infancy, arising in the first few weeks of life and exhibiting a characteristic sequence of growth and spontaneous involution. Most infantile haemangiomas do not require therapy. However, to identify at-risk haemangiomas, close follow-up is crucial in the first weeks of life; 80% of all haemangiomas reach their final size by 3 months of age. The main indications for treatment are life-threatening infantile haemangioma (causing heart failure or respiratory distress), tumours posing functional risks (eg, visual obstruction, amblyopia, or feeding difficulties), ulceration, and severe anatomic distortion, especially on the face. Oral propranolol is now the first-line treatment, which should be administered as early as possible to avoid potential complications. Haemangioma shrinkage is rapidly observed with oral propranolol, but a minimum of 6 months of therapy is recommended.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Age</subject><subject>Atrophy</subject><subject>Babies</subject><subject>Benign</subject><subject>Distortion</subject><subject>Feeding</subject><subject>Heart diseases</subject><subject>Heart Failure - etiology</subject><subject>Hemangioma</subject><subject>Hemangioma - drug therapy</subject><subject>Hemangioma - epidemiology</subject><subject>Humans</subject><subject>Infant</subject><subject>Internal Medicine</subject><subject>Pathogenesis</subject><subject>Propranolol</subject><subject>Propranolol - therapeutic use</subject><subject>Respiratory Distress Syndrome, Newborn - etiology</subject><subject>Shrinkage</subject><subject>Skin Ulcer - etiology</subject><subject>Therapy</subject><subject>Tumors</subject><subject>Visual perception</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkEtLAzEQgIMotlaPHhXBSz2szmweu3tRpPgoFDyo4C1ks7Oauo-6aYX-e7cPK_TiKQS--ZL5GDtBuERAdfUMKCBQEVd9VBcASsgAdlgXRSQCKaK3XdbdIB124P0YAIQCuc86YQxxIiLssuNhlZtq6go6-zBUmurd1aU5ZHu5KTwdrc8ee72_exk8BqOnh-HgdhRYIeJpkBEkaWJTQxxkHJOIOEdKbWy5NGjTUGCGxpjIWslVnoWAuUra0SwzPBQp77H-yjtp6q8Z-akunbdUFKaieuY1xgolIoTYoudb6LieNVX7O40JijgKZSJbSq4o29TeN5TrSeNK08w1gl5008tuehFFt7dlNw3t3OnaPktLyjZTv6Fa4GYFUJvj21GjvXVUWcpcQ3aqs9r9-8T1lsEWrnLWFJ80J_-3jfahhpVk4UC1NAD_AfTnjs4</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Léauté-Labrèze, Christine, Dr</creator><creator>Harper, John I, Prof</creator><creator>Hoeger, Peter H, Prof</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20170701</creationdate><title>Infantile haemangioma</title><author>Léauté-Labrèze, Christine, Dr ; Harper, John I, Prof ; Hoeger, Peter H, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-de09b9cbae30588e47331ebc8c35a1cb241d1aaa7cc536fd201f69448dda324b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Age</topic><topic>Atrophy</topic><topic>Babies</topic><topic>Benign</topic><topic>Distortion</topic><topic>Feeding</topic><topic>Heart diseases</topic><topic>Heart Failure - etiology</topic><topic>Hemangioma</topic><topic>Hemangioma - drug therapy</topic><topic>Hemangioma - epidemiology</topic><topic>Humans</topic><topic>Infant</topic><topic>Internal Medicine</topic><topic>Pathogenesis</topic><topic>Propranolol</topic><topic>Propranolol - therapeutic use</topic><topic>Respiratory Distress Syndrome, Newborn - etiology</topic><topic>Shrinkage</topic><topic>Skin Ulcer - etiology</topic><topic>Therapy</topic><topic>Tumors</topic><topic>Visual perception</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Léauté-Labrèze, Christine, Dr</creatorcontrib><creatorcontrib>Harper, John I, Prof</creatorcontrib><creatorcontrib>Hoeger, Peter H, Prof</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Léauté-Labrèze, Christine, Dr</au><au>Harper, John I, Prof</au><au>Hoeger, Peter H, Prof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infantile haemangioma</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>390</volume><issue>10089</issue><spage>85</spage><epage>94</epage><pages>85-94</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>Summary With a prevalence of 4·5%, infantile haemangiomas are the most common benign tumours of infancy, arising in the first few weeks of life and exhibiting a characteristic sequence of growth and spontaneous involution. Most infantile haemangiomas do not require therapy. However, to identify at-risk haemangiomas, close follow-up is crucial in the first weeks of life; 80% of all haemangiomas reach their final size by 3 months of age. The main indications for treatment are life-threatening infantile haemangioma (causing heart failure or respiratory distress), tumours posing functional risks (eg, visual obstruction, amblyopia, or feeding difficulties), ulceration, and severe anatomic distortion, especially on the face. Oral propranolol is now the first-line treatment, which should be administered as early as possible to avoid potential complications. Haemangioma shrinkage is rapidly observed with oral propranolol, but a minimum of 6 months of therapy is recommended.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28089471</pmid><doi>10.1016/S0140-6736(16)00645-0</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2017-07, Vol.390 (10089), p.85-94 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1861511021 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adrenergic beta-Antagonists - therapeutic use Age Atrophy Babies Benign Distortion Feeding Heart diseases Heart Failure - etiology Hemangioma Hemangioma - drug therapy Hemangioma - epidemiology Humans Infant Internal Medicine Pathogenesis Propranolol Propranolol - therapeutic use Respiratory Distress Syndrome, Newborn - etiology Shrinkage Skin Ulcer - etiology Therapy Tumors Visual perception |
| title | Infantile haemangioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A40%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infantile%20haemangioma&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=L%C3%A9aut%C3%A9-Labr%C3%A8ze,%20Christine,%20Dr&rft.date=2017-07-01&rft.volume=390&rft.issue=10089&rft.spage=85&rft.epage=94&rft.pages=85-94&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(16)00645-0&rft_dat=%3Cproquest_cross%3E1914872595%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1914872595&rft_id=info:pmid/28089471&rft_els_id=S0140673616006450&rfr_iscdi=true |